IFFIm turned slow donor pledges into immediate vaccine money

Vaccine programmes lose value when cash arrives years after a pledge. In 2005, several European donors committed nearly US$4 billion to launch IFFIm, a financing vehicle that would issue bonds against donor promises and frontload money for Gavi.

The structure was simple but powerful: sovereign pledges became collateral-like future cash flows, the World Bank served as treasury manager, and investors bought vaccine bonds. That moved immunisation funding from annual aid calendars into capital markets.

IFFIm's inaugural bonds were issued in London on 14 November 2006 and raised US$1 billion. IFFIm says the bonds priced comparably to sovereign and supranational issuers and were bought by central banks, pension funds, fund managers and insurers.

Gavi says IFFIm had transferred US$6.2 billion to it by 2025, about one sixth of Gavi's overall budget, and that donors had pledged US$9.7 billion through 2037. IFFIm's issuance timeline now reports more than US$11.3 billion raised since creation.

Borrow against promised aid

Legally binding sovereign pledges gave investors credit quality, not charity risk.

Bond issuance moved money to the years when vaccines could be rolled out fastest.

The World Bank treasury role made an unfamiliar health-finance vehicle legible to capital markets.

Investors got a conventional return while the use of proceeds stayed tightly linked to immunisation.

When benefits are time-sensitive but funding arrives slowly, convert credible future commitments into present capital and let markets bridge the timing gap.

IFFIm kept issuing in dollars, sterling, yen-linked retail formats, Australian dollars and sukuk. Gavi used the frontloaded funds for routine immunisation, new vaccine introductions, Ebola response and COVID-19 work, making vaccine bonds a repeatable social-bond template.